<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469948</url>
  </required_header>
  <id_info>
    <org_study_id>CMRPG8BC0781</org_study_id>
    <nct_id>NCT02469948</nct_id>
  </id_info>
  <brief_title>Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities</brief_title>
  <official_title>Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke may result in lower extremity spasticity, which interfere with motor voluntary
      function and activities of daily living. Botulinum toxin type A (BTX-A) has been shown to
      improve lower extremity spasticity of stroke patients. There are no researches to compare the
      efficiency of BTX-A injection by different guidance methods in the deep muscles of lower
      extremity for stroke patients. The aims of investigator's study were to compare the
      effectiveness of BTX-A injection by different guidance methods (palpation of anatomical
      landmarks, ultrasonography direct) in deep spastic muscles of lower extremity for stroke
      patients with varus spasticity and spastic claw toes , and to study the correlation between
      muscles spasticity and elastic properties by the sonoelastography/acoustic radiation force
      impulse imaging and follow the change of elastic properties in spastic muscles after BTX-A
      injection. We will enroll 80 hemiplegic stroke patients with varus spasticity / spastic claw
      toes and duration more than 6 months. Under different guidance methods (palpation of
      anatomical landmarks, electric stimulation, ultrasonography direct and indirect methods),
      BTX-A will be injected to the flexor digitorum longus and posterior tibialis muscles. If the
      patients have moderate hallucis spasticity, flexor hallucis longus muscle will be injected.
      The BTX-A dose is 50 units for each muscle. Outcome measures include Modified Ashworth Scale,
      Brunnstrom stage, muscle power, range of motion, the visual analog scale of pain, Stroke
      Impact Scale, Barthel index and lower extremity function tests, balance test, Goal Attainment
      Scale, sonoelastography and acoustic radiation force impulse imaging. All the assessments
      will be performed before BTX-A injection and followed up at 1 months, 2 months, 3 months and
      6 months after injection. After performing all the assessments, investigator will investigate
      the efficiency of BTX-A by different guidance methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke may result in lower extremity spasticity, which interfere with motor voluntary
      function and activities of daily living. Botulinum toxin type A (BTX-A) has been shown to
      improve lower extremity spasticity of stroke patients. There are no researches to compare the
      efficiency of BTX-A injection by different guidance methods in the deep muscles of lower
      extremity for stroke patients. The aims of investigator's study were to compare the
      effectiveness of BTX-A injection by different guidance methods (palpation of anatomical
      landmarks, electric stimulation, ultrasonography direct and indirect methods) in deep spastic
      muscles of lower extremity for stroke patients with varus spasticity and spastic claw toes ,
      and to study the correlation between muscles spasticity and elastic properties by the
      sonoelastography/acoustic radiation force impulse imaging and follow the change of elastic
      properties in spastic muscles after BTX-A injection. We will enroll 80 hemiplegic stroke
      patients with varus spasticity / spastic claw toes and duration more than 6 months. Under
      different guidance methods (palpation of anatomical landmarks, electric stimulation,
      ultrasonography direct and indirect methods), BTX-A will be injected to the flexor digitorum
      longus and posterior tibialis muscles. If the patients have moderate hallucis spasticity,
      flexor hallucis longus muscle will be injected. The BTX-A dose is 50 units for each muscle.
      Outcome measures include Modified Ashworth Scale, Brunnstrom stage, muscle power, range of
      motion, the visual analog scale of pain, Stroke Impact Scale, Barthel index and lower
      extremity function tests, balance test, Goal Attainment Scale, sonoelastography and acoustic
      radiation force impulse imaging. All the assessments will be performed before BTX-A injection
      and followed up at 1 months, 2 months, 3 months and 6 months after injection. After
      performing all the assessments, investigator will investigate the efficiency of BTX-A by
      different guidance methods.

      Two of arms:

        1. ultrasonography direct-guidance: To inject Botulinum toxin type A on the spasticity
           lower extremity for stroke patients by Ultrasonography direct-guidance.

        2. surface anatomy landmark: To inject Botulinum toxin type A on the spasticity lower
           extremity for stroke patients by surface anatomy landmark.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Ashworth scale</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>activities of daily living</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Test</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tinetti Gait Analysis</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment Score</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ambulation Classification</measure>
    <time_frame>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Ultrasonography direct-guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surface anatomy landmark</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.</description>
    <arm_group_label>Ultrasonography direct-guidance</arm_group_label>
    <arm_group_label>Surface anatomy landmark</arm_group_label>
    <other_name>Botulinum toxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ankle varus spasticity with spasticity claw toes

          -  MP joint and IP joint are above Modified Ashworth Scale 1 +

          -  ankle varus spasticity and spasticity claw toes during walking should reach median
             level

          -  patients feel pain or uncomfortable during walking due to spasticity claw toes.

          -  patients never accept botox, phenol and alcohol injections before.

        Exclusion Criteria:

          -  contracture or deformity on lower extremity

          -  combine other systemic disease of neurological or skelectomuscular system

          -  patients accepted botox, phenol, alcohol injections and operation before.

          -  cognition disorder or aphasia after stroke

          -  Flexor Digitorum Longus, posterior tibialis and Flexor pollicis longus muscle has been
             significant atrophy .

          -  systemic infection

          -  under medication treatment of aminioglycoside or which can change neuromuskular
             transmission medicine

          -  ankle plantarflxeor contracture during walking above median level or the sore of
             Modified Ashworth Scale is above 2 at rest

          -  allergy to botox
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pong Ya-Ping, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rehabilitation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pong Ya-Ping, MD</last_name>
    <phone>889-7-7317123</phone>
    <phone_ext>6286</phone_ext>
    <email>yaping0707@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. Arch Phys Med Rehabil. 2008 Jan;89(1):56-61. doi: 10.1016/j.apmr.2007.08.131.</citation>
    <PMID>18164331</PMID>
  </reference>
  <reference>
    <citation>Caty GD, Detrembleur C, Bleyenheuft C, Deltombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke. 2008 Oct;39(10):2803-8. doi: 10.1161/STROKEAHA.108.516153. Epub 2008 Jul 17.</citation>
    <PMID>18635841</PMID>
  </reference>
  <reference>
    <citation>Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, Schnider P, Altavista MC, Cavazza S, Deltombe T, Duarte E, Geurts AC, Gracies JM, Haboubi NH, Juan FJ, Kasch H, KÃ¤tterer C, Kirazli Y, Manganotti P, Parman Y, Paternostro-Sluga T, Petropoulou K, Prempeh R, Rousseaux M, Slawek J, Tieranta N. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009 Jan;41(1):13-25. doi: 10.2340/16501977-0303.</citation>
    <PMID>19197564</PMID>
  </reference>
  <reference>
    <citation>Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005 May-Jun;25(3):286-91.</citation>
    <PMID>15832139</PMID>
  </reference>
  <reference>
    <citation>Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002 Mar 12;58(5):805-7.</citation>
    <PMID>11889247</PMID>
  </reference>
  <reference>
    <citation>Yang EJ, Rha DW, Yoo JK, Park ES. Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography. Arch Phys Med Rehabil. 2009 May;90(5):741-4. doi: 10.1016/j.apmr.2008.10.025.</citation>
    <PMID>19406292</PMID>
  </reference>
  <reference>
    <citation>O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-80. Review.</citation>
    <PMID>9826989</PMID>
  </reference>
  <reference>
    <citation>Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet. 2004 Jan 17;363(9404):249-50.</citation>
    <PMID>14738817</PMID>
  </reference>
  <reference>
    <citation>Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. Neurotox Res. 2006 Apr;9(2-3):189-96. Review.</citation>
    <PMID>16785117</PMID>
  </reference>
  <reference>
    <citation>Picelli A, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, Tamburin S, Girardi P, Gimigliano R, Smania N. Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: manual needle placement and electrical stimulation guidance compared using ultrasonography. J Rehabil Med. 2012 May;44(5):450-2. doi: 10.2340/16501977-0970.</citation>
    <PMID>22549655</PMID>
  </reference>
  <reference>
    <citation>Picelli A, Tamburin S, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, Santilli V, Smania N. Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques. Am J Phys Med Rehabil. 2012 Nov;91(11):957-64. doi: 10.1097/PHM.0b013e318269d7f3.</citation>
    <PMID>23085706</PMID>
  </reference>
  <reference>
    <citation>Lim EC, Ong BK, Seet RC. Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat Disord. 2006 Jan;12(1):43-7. Epub 2005 Sep 29.</citation>
    <PMID>16198612</PMID>
  </reference>
  <reference>
    <citation>Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil. 2002 Oct;81(10):770-5.</citation>
    <PMID>12362118</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spasticity</keyword>
  <keyword>botulinum toxin</keyword>
  <keyword>ultrasonography guidance</keyword>
  <keyword>electric stimulation guidance</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

